Research ArticleNeuropharmacology
Monoamine Transporter Occupancy of a Novel Triple Reuptake Inhibitor in Baboons and Humans Using Positron Emission Tomography
Robert A. Comley, Cristian A. Salinas, Mark Slifstein, Marcella Petrone, Carmine Marzano, Idriss Bennacef, Paul Shotbolt, Jasper Van der Aart, Marta Neve, Laura Iavarone, Roberto Gomeni, Marc Laruelle, Frank A. Gray, Roger N. Gunn and Eugenii A. Rabiner
Journal of Pharmacology and Experimental Therapeutics August 2013, 346 (2) 311-317; DOI: https://doi.org/10.1124/jpet.112.202895
Robert A. Comley
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Cristian A. Salinas
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Mark Slifstein
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Marcella Petrone
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Carmine Marzano
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Idriss Bennacef
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Paul Shotbolt
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Jasper Van der Aart
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Marta Neve
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Laura Iavarone
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Roberto Gomeni
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Marc Laruelle
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Frank A. Gray
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Roger N. Gunn
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
Eugenii A. Rabiner
Clinical Imaging Centre (R.A.C., C.A.S., C.M., I.B., P.S., J.V., M.L., R.N.G., E.A.R.) and Clinical Pharmacology and Discovery Medicine (F.G.) GlaxoSmithKline, London, United Kingdom; Columbia University, New York, New York (M.S.); and Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Verona, Italy (M.P, M.N., L.I., R.G.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleNeuropharmacology
Occupancy of a Novel Triple Reuptake Inhibitor Using PET
Robert A. Comley, Cristian A. Salinas, Mark Slifstein, Marcella Petrone, Carmine Marzano, Idriss Bennacef, Paul Shotbolt, Jasper Van der Aart, Marta Neve, Laura Iavarone, Roberto Gomeni, Marc Laruelle, Frank A. Gray, Roger N. Gunn and Eugenii A. Rabiner
Journal of Pharmacology and Experimental Therapeutics August 1, 2013, 346 (2) 311-317; DOI: https://doi.org/10.1124/jpet.112.202895
Research ArticleNeuropharmacology
Occupancy of a Novel Triple Reuptake Inhibitor Using PET
Robert A. Comley, Cristian A. Salinas, Mark Slifstein, Marcella Petrone, Carmine Marzano, Idriss Bennacef, Paul Shotbolt, Jasper Van der Aart, Marta Neve, Laura Iavarone, Roberto Gomeni, Marc Laruelle, Frank A. Gray, Roger N. Gunn and Eugenii A. Rabiner
Journal of Pharmacology and Experimental Therapeutics August 1, 2013, 346 (2) 311-317; DOI: https://doi.org/10.1124/jpet.112.202895
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement